



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 12:27
Last Report Issued 01/30/2013 14:48

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2397SP
Patient ID 2397SP
Chain 13000582
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 13000582
Received 01/30/2013 11:55

Sample ID 13000582-001
Matrix Serum or Plasma
Patient Name 2397SP
Patient ID 2397SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

2397SP Indapamide, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Indapamide	None Detected	ng/mL	10	
Synonym(s): Lozol®				

Normal subjects taking 2.5 mg daily normal release indapamide had steady state peak blood concentrations of 150 +/- 35 ng/mL. The blood to plasma ratio for indapamide is approximately 6.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.